AMEX:CVRS

Stock Analysis Report

Corindus Vascular Robotics

Executive Summary

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • Corindus Vascular Robotics has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Corindus Vascular Robotics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

AMEX:CVRS

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

222.7%

AMEX:CVRS

9.1%

US Medical Equipment

2.0%

US Market

CVRS outperformed the Medical Equipment industry which returned 8.7% over the past year.

CVRS outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

CVRSIndustryMarket
7 Day0%-0.9%1.3%
30 Day-0.2%0.7%3.9%
90 Day51.6%4.4%3.4%
1 Year222.7%222.7%10.0%9.1%4.2%2.0%
3 Year258.0%258.0%70.7%65.5%47.2%37.6%
5 Year27.2%27.2%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Corindus Vascular Robotics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Corindus Vascular Robotics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Corindus Vascular Robotics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Corindus Vascular Robotics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Corindus Vascular Robotics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

31.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Corindus Vascular Robotics's revenue is expected to grow significantly at over 20% yearly.

Corindus Vascular Robotics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Corindus Vascular Robotics's revenue growth is expected to exceed the United States of America market average.

Unable to compare Corindus Vascular Robotics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Corindus Vascular Robotics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Corindus Vascular Robotics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Corindus Vascular Robotics performed over the past 5 years?

-12.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Corindus Vascular Robotics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Corindus Vascular Robotics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Corindus Vascular Robotics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Corindus Vascular Robotics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Corindus Vascular Robotics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Corindus Vascular Robotics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Corindus Vascular Robotics's financial position?


Financial Position Analysis

Corindus Vascular Robotics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Corindus Vascular Robotics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Corindus Vascular Robotics's level of debt (80.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (484.7% vs 80.5% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.8x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Corindus Vascular Robotics has sufficient cash runway for 1.1 years based on current free cash flow.

Corindus Vascular Robotics has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.2% each year.


Next Steps

Dividend

What is Corindus Vascular Robotics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Corindus Vascular Robotics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Corindus Vascular Robotics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Corindus Vascular Robotics has not reported any payouts.

Unable to verify if Corindus Vascular Robotics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Corindus Vascular Robotics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Corindus Vascular Robotics's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Mark Toland (49yo)

3.5yrs

Tenure

US$2,194,146

Compensation

Mr. Mark J. Toland has been the Chief Executive Officer, President and Director of Corindus Vascular Robotics, Inc. since March 7, 2016. Mr. Toland joined Corindus from Boston Scientific Corporation, a glo ...


CEO Compensation Analysis

Mark's remuneration is about average for companies of similar size in United States of America.

Mark's compensation has increased whilst company is loss making.


Management Age and Tenure

3.4yrs

Average Tenure

49yo

Average Age

The tenure for the Corindus Vascular Robotics management team is about average.


Board Age and Tenure

3.0yrs

Average Tenure

59yo

Average Age

The tenure for the Corindus Vascular Robotics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$19,71923 May 19
Louis Cannon
EntityIndividual
Role
Member of the Board of Directors
Director
Shares7,500
Max PriceUS$2.63
BuyUS$18,00028 Mar 19
Louis Cannon
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$1.80
BuyUS$4,000,00014 Mar 19
Hudson Executive Capital LP
EntityCompany
Shares2,899,391
Max PriceUS$1.38
BuyUS$791,61213 Mar 19
Biostar Ventures III-XF, L.P.
EntityCompany
Shares573,798
Max PriceUS$1.38

Ownership Breakdown


Management Team

  • Marty Leon

    External Consultant & Executive Advisor

    • Tenure: 3.4yrs
  • David Long (49yo)

    CFO, Senior VP

    • Tenure: 5.1yrs
    • Compensation: US$568.37k
  • Mark Toland (49yo)

    CEO, President & Director

    • Tenure: 3.5yrs
    • Compensation: US$2.19m
  • Doug Teany (47yo)

    Chief Operating Officer

    • Tenure: 3.5yrs
    • Compensation: US$1.04m
  • Nora Dutta

    Senior Vice President of Human Resources

    • Tenure: 3.4yrs
  • J. Grantham

    Chief Medical Officer of Cardiovascular

    • Tenure: 3.1yrs
  • Quill Turk

    Chief Medical Officer of Neuroendovascular

    • Tenure: 1.2yrs

Board Members

  • Jim Tobin (74yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$48.06k
  • Jeff Lightcap (60yo)

    Chairman of the Board

    • Tenure: 5.1yrs
  • Doug Braunstein (58yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$48.89k
  • Louis Cannon (61yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$60.00k
  • Jeff Gold (71yo)

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: US$67.00k
  • Campbell Rogers (58yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$59.00k
  • Mark Toland (49yo)

    CEO, President & Director

    • Tenure: 3.5yrs
    • Compensation: US$2.19m
  • Nathan Harrington (51yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$51.00k

Company Information

Corindus Vascular Robotics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Corindus Vascular Robotics, Inc.
  • Ticker: CVRS
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$888.914m
  • Shares outstanding: 208.67m
  • Website: https://www.corindus.com

Number of Employees


Location

  • Corindus Vascular Robotics, Inc.
  • 309 Waverley Oaks Road
  • Suite 105
  • Waltham
  • Massachusetts
  • 2452
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CVRSAMEX (NYSE MKT LLC)YesNew Common StockUSUSDAug 2014
CR3DB (Deutsche Boerse AG)YesNew Common StockDEEURAug 2014

Biography

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:14
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.